Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/212851
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients |
Autor: | Gutiérrez-Gutiérrez, Belén CSIC ORCID; Rodríguez-Baño, Jesús CSIC ORCID | Palabras clave: | Bloodstream infections Carbapenems Extended-spectrum beta-lactamases Mortality Treatment Urinary tract infections |
Fecha de publicación: | 2019 | Editor: | Elsevier | Citación: | Clinical Microbiology and Infection 25(8): 932-942 (2019) | Resumen: | [Background] Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) are a frequent cause of invasive infections worldwide. Carbapenems are nowadays the most used drugs to treat these infections. However, due to the increasing rates of resistance to these antimicrobials, carbapenem-sparing alternatives are being investigated. [Objectives and sources] The aim of this narrative literature review is to summarize the published information on the currently available antibiotics for the treatment of ESBL-E infections, providing specific information on three subgroups of patients: Group 1, patients with severe infections or infections from high-risk sources or in severely immunocompromised patients; Group 2, patients with non-severe infections from intermediate-risk source; and Group 3, patients with non-severe urinary tract infection. [Content and implications] For patients in Group 1, the current data would support the use of carbapenems. For milder infections, however, particularly urinary tract infections, other non-carbapenem antibiotics can be considered in selected cases, including beta-lactam/beta-lactam inhibitor combinations, cephamycins, temocillin and aminoglycosides. While specific studies should be performed in these situations, individualized decisions may be taken in order to avoid overuse of carbapenems. | Versión del editor: | https://doi.org/10.1016/j.cmi.2019.03.030 | URI: | http://hdl.handle.net/10261/212851 | DOI: | 10.1016/j.cmi.2019.03.030 | Identificadores: | doi: 10.1016/j.cmi.2019.03.030 issn: 1198-743X e-issn: 1469-0691 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
63
checked on 09-abr-2024
WEB OF SCIENCETM
Citations
61
checked on 28-feb-2024
Page view(s)
109
checked on 18-abr-2024
Download(s)
26
checked on 18-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.